Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL30366556 | 0.96 | GAA (0.61) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| Propionamide SCHEMBL1194940 | 0.93 | GAA (0.58) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| Toluene SCHEMBL10972899 | 0.93 | SMN1; SMN2 (0.64) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL13652538 | 0.89 | LMNA (0.70) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL15672957 | 0.88 | EPHX2 (0.56) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL27343037 | 0.86 | MAPT (0.65) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL13652537 | 0.86 | ALDH1A1 (0.61) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL16425162 | 0.85 | MTNR1A (0.49) | GAAEPHX2CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL3087061 | 0.85 | GAA (0.73) | GAAL3MBTL1KMT2AMEN1MCL1 | |
| SCHEMBL30259900 | 0.84 | AOC3 (0.72) | KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103319366-B | Lacosamide synthesis technology | WUHAN INST TECHNOLOGY | 2015-03-11 | — | — | CN | claimed |
| CN-102070484-B | Method for preparing prilocainum or hydrochloride thereof | BENGBU BBCA MEDICINE SCIENCE DEV CO LTD | 2013-10-02 | — | — | CN | claimed |
| CN-103319366-A | Lacosamide synthesis technology | WUHAN INST TECHNOLOGY | 2013-09-25 | — | — | CN | claimed |
| CN-102070484-A | Method for preparing prilocainum or hydrochloride thereof | BENGBU BBCA MEDICINE SCIENCE DEV CO LTD | 2011-05-25 | — | — | CN | claimed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| CN-119300805-A | Skin care compositions and methods of use | 高露洁-棕榄公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118973546-A | Skin care composition comprising vitamin E and vitamin B3 | 高露洁-棕榄公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118973547-A | Skin care composition comprising vitamin E and vitamin B3 | 高露洁-棕榄公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-0395312-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
| EP-0252482-A2 | 7-Acyloxy-6-aminoacyloxypolyoxylabdanes, process for their preparation and their use as medicine | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0217372-A2 | Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
| US-4528379-A | Preparation of substituted thiadiazolyloxyacetamides | BAYER AKTIENGESELLSCHAFT (DE) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | GAA 4729/4885EPHX2 2007/4885CYP3A4 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.